Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 37 (1) , 585-591
Abstract
Introduction: Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For patients with a large burdensome disease, the completeness of cytoreduction sometimes requires maximal effort surgery. The aim of this article is to provide proof of concept for two stage cytoreductive surgery (CRS) in this category of patients. Methods and materials: A two stage CRS and HIPEC with oxaliplatin was proposed for patients with bulky PMP including important involvement of the serosal surfaces of the bowel or colon who had an impaired nutritional status. The residual disease at the end of the first stage was less than 5 mm of thickness on several implants. Clinical, surgical and histopathological variables were analyzed. Results: All eight patients completed the two-stage strategy. Mortality was nil. One Clavien Dindo grade 3 event occurred in each stage. After a median follow up of 29.5 months, all patients were alive and free of recurrence. All of the patients had histopathological complete response on the specimens obtained from the residual sites during the second stage surgery. Conclusions: Two-stage surgical strategy is feasible for bulky PMP patients and it is associated with little high-grade morbidity and enhanced visceral sparing.Keywords
This publication has 24 references indexed in Scilit:
- Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritoneiSurgical Oncology, 2019
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular originBritish Journal of Surgery, 2018
- Pseudomyxoma peritonei: natural history and treatmentInternational Journal of Hyperthermia, 2017
- A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal NeoplasiaAmerican Journal of Surgical Pathology, 2016
- Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative StudyAnnals of Surgical Oncology, 2015
- Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patientsEuropean Journal of Surgical Oncology, 2013
- Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritoneiEuropean Journal of Surgical Oncology, 2012
- Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant DedifferentiationJournal of the American College of Surgeons, 2010
- Long-Term Survival in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: 10 Years of Experience from a Single InstitutionAnnals of Surgical Oncology, 2009
- Successful management of microscopic residual disease in large bowel cancerCancer Chemotherapy and Pharmacology, 1999